2-[4-(4-甲氧基-苯基)-丁基]-异吲哚-1,3-二酮 | 211692-42-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-[4-(4-甲氧基-苯基)-丁基]-异吲哚-1,3-二酮
• 英文名称: 2-[4-(4-methoxy-phenyl)-butyl]-isoindole-1,3-dione
• 英文别名: 2-(4-(4-methoxyphenyl)butyl)isoindoline-1,3-dione；2-[4-(4-methoxyphenyl)butyl]isoindoline-1,3-dione；N-(4-(4-methoxyphenyl)butyl)phthalimide；N-4-(4-methoxyphenyl)butyl phthalimide；2-[4-(4-Methoxyphenyl)butyl]isoindole-1,3-dione
• CAS: 211692-42-1
• 化学式: C₁₉H₁₉NO₃
• 分子量: 309.365
• InChiKey: CCIOFDCZAZODTQ-UHFFFAOYSA-N

物化性质

• 熔点：
  102-103 °C
• 沸点：
  474.5±28.0 °C(Predicted)
• 密度：
  1.199±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-[4-(4-甲氧基-苯基)-丁基]-异吲哚-1,3-二酮 在 一水合肼 作用下， 以 乙醇 为溶剂， 反应 12.0h， 生成 4-(4-甲氧基苯基)丁胺
  参考文献：
  名称：

  α-伯氨基和仲氨基酮的不对称氢化：（-）-arbutamine和（-）-denopamine的有效不对称合成。

  摘要：

  通过使用带有给电子膦配体的Rh催化剂进行不保护的氨基酮的不对称氢化，以高收率和对映选择性制备了两种β受体激动剂（-）-地巴胺和（-）-arbutamine。合成了一系列的α-伯氨基和仲氨基酮并进行氢化，以高收率和良好的对映选择性生产出各种1,2-氨基醇。这种Rh电子给体的膦催化的不对称氢化反应代表了手性氨基醇不对称合成的最有希望和最方便的方法之一。

  DOI：

  10.1002/chem.200700594
• 作为产物：
  描述：

  (3-(1,3-dioxoisoindolin-2-yl)propyl)triphenylphosphonium bromide 在 palladium on activated charcoal 甲醇 、 氢气 、 sodium methylate 作用下， 以 1,4-二氧六环 、 乙醇 为溶剂， 25.0 ℃ 、101.33 kPa 条件下， 反应 15.0h， 生成 2-[4-(4-甲氧基-苯基)-丁基]-异吲哚-1,3-二酮
  参考文献：
  名称：

  Synthesis and Pharmacological Characterization of Novel 6-Fluorochroman Derivatives as Potential 5-HT_1A Receptor Antagonists

  摘要：

  A series of novel 6-fluorochroman derivatives was prepared and evaluated as antagonists for the 5-HT1A receptor. N-2- [[(6-Fluorochroman-8-yl)oxy]ethyl]-4-(4-methoxyphenyl)butylamine (3; J. Med. Chem. 1997, 40, 1252-1257) was chosen as a lead, and structural modifications were done on the aliphatic portion of the chroman ring, the tether linking the middle amine and the terminal aromatic ring, the aromatic ring, and lastly the amine. Radioligand binding assays proved that the majority of the novel compounds behaved as good to excellent ligands at the 5-HT1A receptor, some of which were selective with respect to alpha(1)-adrenergic and D-2-dopaminergic receptors. The antagonist activity of the compounds was assessed in the forskolin-stimulated adenylate cyclase assays in CHO cells expressing the human 5-HT1A receptors. Among the modifications attempted, introduction of an oxo or an optically active hydroxy moiety at the chroman C-4 position was effective in ameliorating the receptor selectivity. Six analogues were selected through the in vitro screeds and further evaluated for their in vivo activities. A 4-oxochroman derivative (31n), having a terminal 1,3-benzodioxole ring, demonstrated antagonist activities toward 8-OH-DPAT-induced behavioral and electrophysiological responses in rats.

  DOI：

  10.1021/jm9707840

文献信息

• Copper-Catalyzed Boron-Selective C(sp²)–C(sp³) Oxidative Cross-Coupling of Arylboronic Acids and Alkyltrifluoroborates Involving a Single-Electron Transmetalation Process
  作者：Siyi Ding、Liang Xu、Pengfei Li

  DOI：10.1021/acscatal.5b02524

  日期：2016.2.5

  A rapid and highly selective oxidative cross-coupling reaction between readily available and shelf-stable arylboronic acids and primary or secondary potassium alkyltrifluoroborates was devised and developed, which works under mild conditions using copper(II) acetate as the catalyst and silver oxide as the oxidant. Initial experimental results indicate that a single-electron transmetalation process

  设计并开发了一种易于使用且易于储存的芳基硼酸与烷基三氟硼酸钾仲烷基钾或仲烷基硼酸钾之间的快速且高度选择性的氧化交叉偶联反应，该反应在温和的条件下以乙酸铜（II）为催化剂，氧化银为氧化剂而起作用。初步的实验结果表明，涉及单电子重金属化过程。这种方法有效地绕过了与烷基硼酸酯的传统交叉偶联反应相关的问题，从而为构建C（sp 2）–C（sp 3）键提供了一种补充方法。
• Alkyl Carbagermatranes Enable Practical Palladium-Catalyzed sp²–sp³ Cross-Coupling
  作者：Meng-Yu Xu、Wei-Tao Jiang、Ying Li、Qing-Hao Xu、Qiao-Lan Zhou、Shuo Yang、Bin Xiao

  DOI：10.1021/jacs.9b02776

  日期：2019.5.8

  be highly reactive in cross-coupling reactions with our newly developed electron-deficient phosphine ligands. Generally, secondary alkyl carbagermatranes show slightly lower, yet comparable activity to its Sn analogue. Meanwhile, primary alkyl carbagermatranes exhibit high activity, and they were also proved stable enough to be compatible with various reactions. Chiral secondary benzyl carbagermatrane

  钯催化的交叉偶联反应在过去几十年中取得了巨大的成就。然而，由于与 C(sp2) 杂交对应物相比，C(sp3) 杂交亲核试剂的金属转移缓慢，因此它们通常仍然是具有挑战性的偶联伙伴。虽然使用 C(sp3)-杂化亲核试剂的基于单电子转移的策略最近取得了重大进展，但在涉及 C(sp3)-杂化亲核试剂的传统双电子机制方面取得的突破较少。在本报告中，我们展示了一系列独特的烷基卡巴格马酯，它们被证明在与我们新开发的缺电子膦配体的交叉偶联反应中具有高反应性。通常，仲烷基卡巴格马特拉的活性略低，但与其 Sn 类似物的活性相当。同时，伯烷基卡巴杰马酯具有高活性，并且它们也被证明足够稳定以与各种反应相容。手性仲苄基卡巴杰马特拉在无碱/无添加剂条件下得到偶联产物，其构型完全反转，表明金属转移是在“SE2(open) Inv”途径中进行的，这与 Hiyama 之前的观察结果一致。值得注意的是，伯烷基卡巴格马特拉的交
• Development of a New Class of Nonimidazole Histamine H₃ Receptor Ligands with Combined Inhibitory Histamine <i>N-</i>Methyltransferase Activity
  作者：Joachim Apelt、Xavier Ligneau、Heinz H. Pertz、Jean-Michel Arrang、C. Robin Ganellin、Jean-Charles Schwartz、Walter Schunack、Holger Stark

  DOI：10.1021/jm0110845

  日期：2002.2.1

  class of nonimidazole histamine H(3) receptor ligands were developed that simultaneously possess strong inhibitory activity on the main histamine metabolizing enzyme, histamine N-methyltransferase (HMT). The novel compounds contain an aminoquinoline moiety, which is an important structural feature for HMT inhibitory activity, connected by different spacers to a piperidino group (for H(3) receptor antagonism)

  在寻找增强中枢神经系统中组胺能神经传递的新颖方法的同时，开发了一种新型的非咪唑组胺H（3）受体配体，该配体同时对主要组胺代谢酶组胺N-甲基转移酶（HMT）具有较强的抑制活性。新化合物包含氨基喹啉部分，这是HMT抑制活性的重要结构特征，通过不同的间隔基连接到哌啶子基上（对H（3）受体有拮抗作用）。间隔物结构的变化提供了两种不同系列的化合物。一个系列，在基本中心之间只有一个亚烷基间隔基，导致对人组胺H（3）受体具有中等至高亲和力的高效HMT抑制剂。第二系列具有对苯氧丙基间隔基 可以被另一个亚烷基链延长。后一个系列还显示出对HMT的强抑制活性，并且在大多数情况下，H（3）受体的亲和力甚至超过了第一个系列。具有这种双重作用方式的最有效的化合物之一是4-（4-（3-哌啶子基丙氧基）苯氨基）喹啉（34）（hH（3），K（i）= 0.09 nM; HMT，IC（50）= 51 nM）。这类化合物在豚鼠对
• [EN] BENZOXAZOLONE DERIVATIVES AS ACID CERAMIDASE INHIBITORS, AND THEIR USE AS MEDICAMENTS<br/>[FR] DÉRIVÉS DE BENZOXAZOLONE EN TANT QU'INHIBITEURS DE LA CÉRAMIDASE ACIDE, ET LEUR UTILISATION COMME MÉDICAMENTS
  申请人：FOND ISTITUTO ITALIANO DI TECNOLOGIA

  公开号：WO2015173168A1

  公开（公告）日：2015-11-19

  The present invention relates to benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides benzoxazolone derivatives for use as a medicament in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.

  本发明涉及苯并噁唑酮衍生物作为酸酶抑制剂，含有这些抑制剂的药物组合物以及用于抑制酸酶治疗临床相关的调节神经酰胺水平的疾病的方法。该发明还提供苯并噁唑酮衍生物作为药物在治疗癌症、炎症、疼痛、炎症性疼痛或肺部疾病中的用途。
• Benzoxazolone derivatives as acid ceramidase inhibitors, and their use as medicaments
  申请人：FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA

  公开号：US10226452B2

  公开（公告）日：2019-03-12

  The present invention relates to benzoxazolone derivatives as acid ceramidase inhibitors, pharmaceutical compositions containing these inhibitors and methods of inhibiting acid ceramidase for the treatment of disorders in which modulation of the levels of ceramide is clinically relevant. The invention also provides benzoxazolone derivatives for use as a medicament in the treatment of cancer, inflammation, pain, inflammatory pain or pulmonary diseases.

  本发明涉及作为酸性神经酰胺酶抑制剂的苯并恶唑酮衍生物、含有这些抑制剂的药物组合物和抑制酸性神经酰胺酶的方法，用于治疗神经酰胺水平的调节与临床相关的疾病。本发明还提供了用作治疗癌症、炎症、疼痛、炎性疼痛或肺部疾病的药物的苯并恶唑酮衍生物。